GLP-1 Triple Stack
Goal · Reference framework comparing the three lead next-generation incretin and amylin research compounds.
This is a reference framing for the three lead next-generation body-composition research compounds. GLP-2 is the dual GLP-1R + GIPR agonist (FDA-approved as GLP-2 prescription analog and GLP-2 prescription analog). GLP-1 adds glucagon-receptor agonism as a third arm (investigational, Phase 3 TRIUMPH). Cagrilintide is the long-acting amylin + calcitonin receptor agonist used as the satiety complement in CagriSema (investigational, Phase 3 REDEFINE). The three compounds cover three distinct receptor systems (GLP-1, GIP, GCGR, amylin/calcitonin). Buyers researching the obesity-research category often acquire all three for parallel in-vitro characterization, not simultaneous use.
COMPONENTS
Triple GLP-1R / GIPR / GCGR agonism (investigational)
Dual GLP-1R / GIPR agonism (FDA-approved as GLP-2 prescription analog / GLP-2 prescription analog)
Long-acting amylin + calcitonin receptor agonism (satiety pathway)
CYCLE FRAMING
Reference-only framing · not a combination protocol
RESEARCH NOTE
Co-administration of multiple incretin or amylin agonists is not supported by published research. They engage overlapping pathways and combined use is unstudied.
SOURCED FROM PEPPU LABS
Each component is available individually as research-grade material at Peppu Studio · ≥99% purity · per-batch CoA. For laboratory research use only. No human dose is recommended.